Humana (HUM) Shares Jump 12% on Superior Medicare Rate hike, Defying Analyst Forecasts

TLDR

• The Centers for Medicare and Medicaid Services (CMS) has finalized a 2.48% Medicare Advantage rate increase for 2027, a figure far higher than the 0.09% proposal unveiled in January.
• Humana (HUM) jumped 12% in after-hours trading, while UnitedHealth (UNH) and CVS Health (CVS) rose more than 6% during premarket sessions.
• The final rate translates to over $13 billion in additional Medicare Advantage payments to insurers in 2027.
• Hospital and managed care stocks also rallied, with Molina Healthcare (MOH) up 7% and Centene (CNC) rising 4%.
• Mizuho analyst Jared Holz noted the rate is “certainly better than the government’s initial rate decision,” but added that it is not exceptional on its own.

---

(SeaPRwire) –   Humana (HUM) opened around 11% higher on Tuesday, following Monday’s after-hours announcement of the final 2027 Medicare Advantage payment rates.

Humana Inc., HUM

The 2.48% final rate marks a significant jump from the 0.09% proposed rate in January, which caught the industry off guard and pushed insurer stocks lower at the time.

The CMS announcement means private health insurers will receive more than $13 billion in additional Medicare Advantage payments from the government in 2027.

UnitedHealth (UNH) and CVS Health (CVS), the parent company of Aetna, both gained over 6% in premarket trading on Tuesday. Elevance Health (ELV) climbed roughly 5%. Hospital and managed care stocks also got a lift, with Molina Healthcare (MOH) up 7% and Centene (CNC) rising 4%.

This stock rally came after months of lobbying from insurers and their trade groups, who argued the January proposal did not reflect rising medical costs. The Better Medicare Alliance had called the near-zero initial proposal a functional “cut,” pointing to annual medical cost trends of 7% to 9%.

What Changed in the Final Rate

CMS implemented several technical updates alongside the headline rate. Starting in 2027, the agency will exclude diagnosis data from unlinked chart review records when calculating risk scores, with a carve-out for beneficiaries switching between Medicare Advantage organizations.

The agency said this change will have a larger impact on plans that rely heavily on those chart reviews to document patient diagnoses and secure higher payments. CMS also updated the Part D risk adjustment model to account for changes under the Inflation Reduction Act.

CMS Administrator Dr. Mehmet Oz said the updates aim to keep “coverage affordable” and ensure patients get “real value from their plans.”

Wall Street had been cautious ahead of Monday’s announcement. TD Cowen’s Ryan Langston had projected a more modest increase in the 1% to 1.5% range. The 2.48% outcome exceeded those expectations, though Mizuho’s Jared Holz tempered enthusiasm: “We do not believe a Medicare rate increase of 2.5% is so impressive in a vacuum, but is certainly better than the government’s initial rate decision.”

Holz said there is now “a chance for margins to expand next year, provided the Companies continue to trim benefits and align costs with revenue.”

The Stakes Behind the Rate

Medicare Advantage covers around 35 million beneficiaries and has grown steadily to surpass enrollment in traditional government-run Medicare. The final rate governs how more than half a trillion dollars flows through private health plans each year, making it one of the most closely watched data points in the health insurance sector.

The rate includes factors such as underlying cost growth, 2026 Star Ratings for quality bonus payments, and risk adjustment methodology updates. CMS confirmed it will continue using the 2024 Medicare Advantage risk adjustment model for 2027.

Bipartisan pressure to rein in Medicare Advantage spending added uncertainty to the process. Both parties have raised questions about insurer coding practices that can lead to higher payments for patients with more recorded diagnoses. The Biden-era CMS had already started tightening those payments, and the January proposal under the Trump administration signaled that scrutiny would continue.